| Literature DB >> 26612284 |
De-Wei Wu, Meng-Yue Yu1, Hai-Yang Gao, Zhe He, Jing Yao, Cheng Ding, Bo Xu, Li Zhang, Fei Song, Qing-Rong Liu, Yong-Jian Wu.
Abstract
BACKGROUND: Peri-strut low-intensity area (PLIA) is a typical image pattern of neointima detected by optical coherence tomography (OCT) after stent implantation. However, few studies evaluated the predictors and prognosis of the PLIA; therefore, we aimed to explore the genesis and prognosis of PLIA detected by OCT in this study.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26612284 PMCID: PMC4794892 DOI: 10.4103/0366-6999.170268
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Figure 1Optical coherence tomography images of peri-strut region. (a) Representative image of peri-strut low-intensity, (b) representative image of peri-strut high-intensity.
Figure 2Different image patterns detected by optical coherence tomography. (a) Macrophage showed bright spots at the surface of intima (white arrow). (b) The measurement of neoatheroma cap thickness (label “A” and short white line). Neoatheroma with cap thickness <65 μm was defined as TCNA. (c) Microvessel showed delineated low backscatter structures <200 μm in diameter (white arrow). Cross-sections with one or more positive sites of macrophage, TCNA, or microvessel were defined positive for the specific image pattern. TCNA: Thin cap neoatheroma.
Baseline characteristics of patients with neointimal hyperplasia assessed by OCT
| Items | Low-intensity ( | High-intensity ( | Statistical values | |
|---|---|---|---|---|
| Stent implantation time (years) | 0.37 (0.30–1.11) | 1.07 (0.45–4.05) | 704* | 0.004 |
| Follow-up time (years) | 3.68 (3.30–3.86) | 3.88 (3.43–4.08) | 510* | 0.208 |
| Clinical variables | ||||
| Age (years) | 66.1 ± 6.8 | 62.7 ± 9.5 | 1.57† | 0.119 |
| Male | 17 (77.3) | 95 (89.6) | 2.54‡ | 0.111 |
| ACS | 5 (22.7) | 7 (6.6) | 5.58‡ | 0.033 |
| Smoke | 7 (31.8) | 50 (38.1) | 0.59‡ | 0.303 |
| Hypertension | 14 (63.6) | 64 (60.4) | 0.08‡ | 0.487 |
| Diabetes | 9 (40.9) | 31 (29.2) | 1.15‡ | 0.204 |
| Hyperlipidemia | 16 (72.7) | 64 (60.4) | 1.19‡ | 0.200 |
| Cerebrovascular disease | 5 (22.7) | 2 (1.9) | 15.31‡ | 0.002 |
| Peripheral vascular disease | 0 (0) | 1 (0.9) | 0.21‡ | 0.828 |
| Prior MI | 11 (50.0) | 48 (45.3) | 0.16‡ | 0.432 |
| Prior PCI | 4 (18.2) | 19 (18.1) | 0.00‡ | 0.600 |
| Prior CABG | 1 (4.5) | 2 (1.9) | 0.55‡ | 0.438 |
| Laboratory tests | ||||
| PLT (×109/L) | 189 (171–231) | 183 (156–221) | 982* | 0.244 |
| HbA1c (%) | 6.10 (5.70–7.18) | 6.10 (5.70–6.60) | 990* | 0.833 |
| Scr (μmol/L) | 79.01 ± 18.21 | 78.93 ± 15.30 | 0.02† | 0.981 |
| Triglyceride (mmol/L) | 2.42 ± 1.03 | 1.87 ± 0.84 | 2.58† | 0.010 |
| TC (mmol/L) | 5.46 ± 1.09 | 4.71 ± 0.97 | 3.16† | 0.002 |
| LDL (mmol/L) | 2.39 ± 0.98 | 1.91 ± 0.62 | 2.14† | 0.041 |
| HDL (mmol/L) | 1.12 ± 0.27 | 1.06 ± 0.26 | 0.87† | 0.385 |
| hsCRP (mg/L) | 1.82 (1.78–3.50) | 1.64 (0.86–3.46) | 961* | 0.422 |
| Usage of medication | ||||
| Aspirin | 22 (100.0) | 106 (100.0) | – | – |
| Clopidogrel | 22 (100.0) | 97 (94.2) | 1.35‡ | 0.305 |
| β-block | 21 (95.5) | 94 (91.3) | 0.43‡ | 0.444 |
| ACEI/ARB | 15 (68.2) | 68 (66.0) | 0.04‡ | 0.529 |
| Statin | 21 (95.5) | 101 (98.1) | 0.53‡ | 0.443 |
Values are median (IQR), mean ± SD or n (%); *: U values, †: t values, ‡: χ2 values, IQR: Interquartile range; SD: Standard deviation; ACS: Acute coronary syndrome; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; PLT: Platelet; HbA1c: Hemoglobin A1c; Scr: Serum creatinine; TC: Total cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; hsCRP: Hypersensitivity C-reaction protein; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; OCT: Optical coherence tomography.
OCT assessment of neointima between low and high-intensity groups
| Items | Low- intensity ( | High- intensity ( | Statistical values | |
|---|---|---|---|---|
| Cross-sections ( | 396 | 1806 | ||
| Restenosis ratio (%) | 26.59 ± 5.50 | 27.60 ± 6.92 | −1.87† | 0.062 |
| Average intimal thickness (mm) | 0.12 ± 0.09 | 0.13 ± 0.05 | −1.03† | 0.240 |
| Microvessels* | 19 (4.8) | 429 (23.8) | 72.01‡ | <0.001 |
| Macrophage* | 107 (27.0) | 437 (24.2) | 1.39‡ | 0.133 |
| TCNA* | 28 (7.1) | 85 (4.7) | 3.73‡ | 0.039 |
Values are mean ± SD or n (%); *With one or more in each cross-section, †: t values, ‡: χ2 values; SD: Standard deviation; OCT: Optical coherence tomography; TCNA: Thin cap neoatheroma.
Factors related to peri-strut low-intensity detected by OCT
| Factors | 95% | ||
|---|---|---|---|
| ACS | 18.77 | 2.73–128.83 | 0.003 |
| Stent implantation time | 0.57 | 0.33–0.98 | 0.043 |
| LDL | 2.61 | 1.22–5.66 | 0.015 |
| Triglyceride | 2.11 | 1.14–3.90 | 0.017 |
| Cerebrovascular disease | 101.11 | 6.54–1562.13 | <0.001 |
ACS: Acute coronary syndrome; LDL: Low-density lipoprotein; OCT: Optical coherence tomography; OR: Odds ratio; CI: Confidence interval.
Major adverse cardiac events and angina pectoris during follow-up after OCT reexamination
| Endpoints | Low-intensity ( | High-intensity ( | 95% | ||
|---|---|---|---|---|---|
| MACEs | 1 (5.6) | 6 (7.7) | 1.63 | 0–138,424.6 | 0.932 |
| Cardiac death | 0 (0) | 0 (0) | |||
| MI | 0 (0) | 0 (0) | |||
| TLR | 1 (5.6) | 6 (7.7) | 1.63 | 0–138,424.6 | 0.932 |
| All angina | 9 (50.0) | 36 (46.2) | 1.14 | 0.39–3.37 | 0.811 |
| SAP | 5 (27.8) | 29 (37.2) | 0.32 | 0.07–1.50 | 0.149 |
| UA | 7 (38.9) | 10 (12.8) | 6.16 | 1.25–30.33 | 0.025 |
| Rehospitalization | 7 (38.9) | 26 (33.3) | 0.96 | 0.23–4.01 | 0.955 |
Values are n (%); After adjusted for age, gender, hypertension, diabetes, hyperlipidemia, smoke, history of cerebrovascular disease, initial presentation of ACS, TC, LDL, and triglyceride; MACEs: Major adverse cardiovascular events; MI: Myocardial infarction; TLR: Target lesion revascularization; SAP: Stable angina pectoris; UA: Unstable angina; ACS: Acute coronary syndrome; TC: Total cholesterol; LDL: Low-density lipoprotein; OCT: Optical coherence tomography; CI: Confidence interval; HR: Hazard ratio.